Poseltinib
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02628028)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1- Mol. weight
- 470.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4163691 ↗
Also known as
- ly3337641
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05335018 | Phase 2 | May 30, 2022 | Seoul National University |
| NCT03099148 | Phase 1 | Apr 4, 2017 | Eli Lilly |
| NCT03083561 | Phase 1 | Mar 15, 2017 | Eli Lilly |
| NCT02914379 | Phase 1 | Sep 1, 2016 | Eli Lilly |
| NCT02628028 | Phase 2 | Aug 1, 2016 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 2 | 2016 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1